257 related articles for article (PubMed ID: 29417559)
1. Imatinib-induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature.
Di Tullio F; Mandel VD; Scotti R; Padalino C; Pellacani G
Int J Dermatol; 2018 Jul; 57(7):784-790. PubMed ID: 29417559
[TBL] [Abstract][Full Text] [Related]
2. Mucosal pigmentation of the hard palate in a patient taking imatinib.
Lyne A; Creedon A; Bailey BM
BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25883257
[TBL] [Abstract][Full Text] [Related]
3. Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review.
Oliveira SR; de Azevedo Branco LG; Rocha AL; Travassos DV; Magalhães GHR; Fonseca FP; Mesquita RA; Abreu LG; da Silva TA
Clin Oral Investig; 2019 Dec; 23(12):4371-4382. PubMed ID: 30968242
[TBL] [Abstract][Full Text] [Related]
4. Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients.
Vinay K; Yanamandra U; Dogra S; Handa S; Suri V; Kumari S; Khadwal A; Prakash G; Lad D; Varma S; Malhotra P
Int J Dermatol; 2018 Mar; 57(3):332-338. PubMed ID: 29266186
[TBL] [Abstract][Full Text] [Related]
5. The blue palate-A case series of imatinib-related oral pigmentation and literature review.
Donnell CC; Walton RL; Carrozzo M
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Jan; 131(1):49-61. PubMed ID: 33199217
[TBL] [Abstract][Full Text] [Related]
6. A Large Gray-Blue Macule on the Hard Palate as an Adverse Effect of Imatinib.
Lueken N; Kaune KM; Zutt M
Dtsch Arztebl Int; 2019 Feb; 116(6):95. PubMed ID: 30892185
[No Abstract] [Full Text] [Related]
7. Hyperpigmentation due to imatinib: A rare case of cutaneous involvement.
Rehman H; Hakim N; Sugarman R; Seetharamu N; Saif MW
J Oncol Pharm Pract; 2020 Sep; 26(6):1511-1515. PubMed ID: 32067560
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate induced erythroderma: A rare case series.
Kumar S; Mahajan BB; Kaur S; Banipal RP; Singh A
J Cancer Res Ther; 2015; 11(4):993-6. PubMed ID: 26881566
[TBL] [Abstract][Full Text] [Related]
9. A case series of imatinib-induced generalized hypopigmentation and progression of existing acquired dermal melanocytosis.
Kok WL; Chen Q; Lee SSJ; Chua SH; Ng SK
J Dermatolog Treat; 2017 Dec; 28(8):762-763. PubMed ID: 28481685
[TBL] [Abstract][Full Text] [Related]
10. Pigmentary changes in a patient treated with imatinib.
Balagula Y; Pulitzer MP; Maki RG; Myskowski PL
J Drugs Dermatol; 2011 Sep; 10(9):1062-6. PubMed ID: 22052279
[TBL] [Abstract][Full Text] [Related]
11. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases.
Mattsson U; Halbritter S; Mörner Serikoff E; Christerson L; Warfvinge G
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 May; 111(5):e12-6. PubMed ID: 21330162
[TBL] [Abstract][Full Text] [Related]
12. PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.
Guru SA; Mir R; Bhat M; Najar I; Zuberi M; Sumi M; Masroor M; Gupta N; Saxena A
Tumour Biol; 2017 Oct; 39(10):1010428317713857. PubMed ID: 29019285
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up.
Dervis E; Ayer M; Akin Belli A; Barut SG
Eur J Dermatol; 2016 Apr; 26(2):133-7. PubMed ID: 26679005
[TBL] [Abstract][Full Text] [Related]
14. Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
Musolino C; Allegra A; Mannucci C; Russo S; Alonci A; Maisano V; Calapai G; Gangemi S
Turk J Haematol; 2015 Jun; 32(2):168-71. PubMed ID: 26316486
[TBL] [Abstract][Full Text] [Related]
15. Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib.
Steele JC; Triantafyllou A; Rajlawat BP; Field EA
Clin Exp Dermatol; 2012 Jun; 37(4):432-3. PubMed ID: 22420895
[No Abstract] [Full Text] [Related]
16. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
Wong M; Sade S; Gilbert M; Klieb HB
Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
[TBL] [Abstract][Full Text] [Related]
17. Imatinib Mesylate Induced Erythroderma.
Lunge S; Bhise R
J Assoc Physicians India; 2018 Dec; 66(12):79-80. PubMed ID: 31313559
[TBL] [Abstract][Full Text] [Related]
18. Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib.
Bombeccari GP; Garagiola U; Pallotti F; Rossi M; Porrini M; Giannì AB; Spadari F
Maxillofac Plast Reconstr Surg; 2017 Dec; 39(1):37. PubMed ID: 29230387
[TBL] [Abstract][Full Text] [Related]
19. Successful hyaluronic acid filler injection in a chronic myeloid leukemia patient taking imatinib mesylate.
Sung Y; Kim MH; Cho E
J Cosmet Laser Ther; 2019; 21(4):243-244. PubMed ID: 30285513
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
